c-Met is a marker of pancreatic cancer stem cells and therapeutic target - PubMed (original) (raw)
. 2011 Dec;141(6):2218-2227.e5.
doi: 10.1053/j.gastro.2011.08.009. Epub 2011 Aug 22.
Affiliations
- PMID: 21864475
- DOI: 10.1053/j.gastro.2011.08.009
c-Met is a marker of pancreatic cancer stem cells and therapeutic target
Chenwei Li et al. Gastroenterology. 2011 Dec.
Abstract
Background & aims: Growth of many different tumor types requires a population of self-renewing cancer stem cells (CSCs). c-Met is a marker of normal mouse pancreatic stem and progenitor cells; we investigated whether it is also a marker of human pancreatic CSCs that might be developed as a therapeutic target.
Methods: We studied growth of primary human pancreatic adenocarcinoma in NOD SCID mice. The self-renewal capability of pancreatic cancer cells that expressed high levels of c-Met (c-Met(high)) was assessed using in vitro sphere assays and compared with those that were c-Met negative or expressed low levels of c-Met. The tumorigenicity of c-Met(high) pancreatic cancer cells was evaluated in NOD SCID mice.
Results: c-Met(high) cells readily formed spheres, whereas c-Met-negative cells did not. Use of the c-Met inhibitor XL184 or c-Met knockdown with small hairpin RNAs significantly inhibited tumor sphere formation. c-Met(high) cells had increased tumorigenic potential in mice; those that expressed c-Met and CD44 (0.5%-5% of the pancreatic cancer cells) had the capability for self-renewal and the highest tumorigenic potential of all cell populations studied. In pancreatic tumors established in NOD SCID mice, c-Met inhibitors slowed tumor growth and reduced the population of CSCs when given alone or in combination with gemcitabine. Administration of XL184 for 2 weeks after cardiac injection of cancer cells prevented the development of metastases.
Conclusions: c-Met is a new marker for pancreatic CSCs. It is required for growth and metastasis of pancreatic tumors in mice and is a therapeutic target for pancreatic cancer.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
- c-Met in pancreatic cancer stem cells: therapeutic implications.
Herreros-Villanueva M, Zubia-Olascoaga A, Bujanda L. Herreros-Villanueva M, et al. World J Gastroenterol. 2012 Oct 14;18(38):5321-3. doi: 10.3748/wjg.v18.i38.5321. World J Gastroenterol. 2012. PMID: 23082047 Free PMC article. - CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
Hong SP, Wen J, Bang S, Park S, Song SY. Hong SP, et al. Int J Cancer. 2009 Nov 15;125(10):2323-31. doi: 10.1002/ijc.24573. Int J Cancer. 2009. PMID: 19598259 - The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.
Hage C, Rausch V, Giese N, Giese T, Schönsiegel F, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Herr I. Hage C, et al. Cell Death Dis. 2013 May 9;4(5):e627. doi: 10.1038/cddis.2013.158. Cell Death Dis. 2013. PMID: 23661005 Free PMC article. - Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
Niess H, Camaj P, Renner A, Ischenko I, Zhao Y, Krebs S, Mysliwietz J, Jäckel C, Nelson PJ, Blum H, Jauch KW, Ellwart JW, Bruns CJ. Niess H, et al. Target Oncol. 2015 Jun;10(2):215-27. doi: 10.1007/s11523-014-0323-z. Epub 2014 Jun 22. Target Oncol. 2015. PMID: 24950733 - C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell.
Lim YC, Kang HJ, Moon JH. Lim YC, et al. Oral Oncol. 2014 Jul;50(7):633-9. doi: 10.1016/j.oraloncology.2014.04.004. Epub 2014 May 15. Oral Oncol. 2014. PMID: 24835851 Review.
Cited by
- A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma.
Ferrara B, Dugnani E, Sordi V, Pasquale V, Pellegrini S, Reni M, Balzano G, Piemonti L. Ferrara B, et al. Int J Mol Sci. 2022 Sep 14;23(18):10663. doi: 10.3390/ijms231810663. Int J Mol Sci. 2022. PMID: 36142575 Free PMC article. - The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma.
Evan T, Wang VM, Behrens A. Evan T, et al. Oncogene. 2022 Oct;41(42):4686-4695. doi: 10.1038/s41388-022-02448-x. Epub 2022 Sep 10. Oncogene. 2022. PMID: 36088504 Free PMC article. Review. - Isolation, culture and genetic manipulation of mouse pancreatic ductal cells.
Reichert M, Takano S, Heeg S, Bakir B, Botta GP, Rustgi AK. Reichert M, et al. Nat Protoc. 2013;8(7):1354-65. doi: 10.1038/nprot.2013.079. Epub 2013 Jun 20. Nat Protoc. 2013. PMID: 23787893 Free PMC article. - Concise Review: Pancreatic Cancer and Bone Marrow-Derived Stem Cells.
Błogowski W, Bodnarczuk T, Starzyńska T. Błogowski W, et al. Stem Cells Transl Med. 2016 Jul;5(7):938-45. doi: 10.5966/sctm.2015-0291. Epub 2016 May 23. Stem Cells Transl Med. 2016. PMID: 27217346 Free PMC article. Review. - The Role of Hepatocyte Growth Factor (HGF) in Insulin Resistance and Diabetes.
Oliveira AG, Araújo TG, Carvalho BM, Rocha GZ, Santos A, Saad MJA. Oliveira AG, et al. Front Endocrinol (Lausanne). 2018 Aug 30;9:503. doi: 10.3389/fendo.2018.00503. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 30214428 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous